Biotech Values

[DewDiligence]

Academic study says UK’s NICE paying too much for new drugs:

http://www.pharmatimes.com/Article/15-02-19/Pharma_and_NICE_reject_view_NHS_pays_too_much_for_meds.aspx

The analysis notes that currently NICE uses a threshold of £30,000 [~$46K] per Quality Adjusted Life Year (QALY) but claims this should be £13,000 to provide most benefit across the NHS. The present level is leading to increased mortality in cancer, circulatory, respiratory or gastro-intestinal diseases and reduced quality of life in neurological diseases and mental health, the researchers argue.